GLP1R and hydrops fetalis: The benefits on HF outcomes observed with the use of GLP-1 receptor agonists may be due to their direct effects through actions on endothelial dysfunction and inflammation (34), reducing the circulating immune cell and chemokine levels, the vascular expression of pro-inflammatory mediators and leukocyte adhesion molecules, and the vascular infiltration by immune cells (35).